Navigation Links
Sinapis Pharma To Present at Rodman & Renshaw Conference
Date:9/8/2009

JACKSONVILLE, Fla., Sept. 8 /PRNewswire/ -- Sinapis Pharma announces that it will present an overview of its stroke and traumatic brain injury treatment data at the Rodman & Renshaw Annual Global Investment Conference at the Palace Hotel in New York City this Friday, September 11, 2009, at 3:15 PM ET. Sinapis has discovered and has patents-pending for a novel use and route of administration of an FDA-approved drug that will be in clinical development in the near future. Further information can be found at www.sinapispharma.com or the conference website www.rodmanandrenshaw.com/conferences.


'/>"/>
SOURCE Sinapis Pharma, Inc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. FDA pharmaceutical import alert
2. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
3. KV Pharmaceutical Appoints Interim Chief Financial Officer
4. Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies
5. Pharmacists Urge the Public to Begin Getting Immunized
6. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
7. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Giant Eagle Pharmacy to Offer Customers in Ohio a Dose of Economic Relief Through Free Antibiotics Program
10. Giant Eagle Pharmacy to Offer Customers in Pennsylvania a Dose of Economic Relief Through Free Antibiotics Program
11. Americas No. 1 Pharmacy Names Great Health as Its Exclusive Health and Wellness Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics 2Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 2Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 3Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 4Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 5Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 6Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 7Health News:Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione 2Health News:Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione 3Health News:Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer 2Health News:Scientific Publications Strategy & Delivery Shifts from Marketing to Medical 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 3Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years 4
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 1Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 2Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 3Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 1Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 2DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 1DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 2
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures 2